Circulating endothelial progenitor cells as a marker of left ventricular pump function in ischemic chronic heart failure

Authors

DOI:

https://doi.org/10.14739/2409-2932.2017.3.113561

Keywords:

heart failure, preserved left ventricular function, biomarkers, endothelial progenitor cells

Abstract

The goal of the study was to explore whether the quantity of endothelial progenitor cells (EPCs) associates with ischemic chronic heart failure (CHF) phenotypes.

Materials and methods. Inclusion criteria met 82 patients with ischemic CHF. Sick persons with global left ventricular ejection fraction >40 % were graded as the HFpEF group (n = 39) and others with ≤40 % as the HFrEF group (n = 43). The levels of biomarkers in serum were measured at starting point. The method of flow cytometry was used for predictably distinguishing circulating cell subsets depending on expression of CD45, CD34, CD14, Tie-2, and CD309 antigens.

Results. In multivariate logistic regression model galectin-3 (R2 = 0.67;P = 0.012), T2DM (R2 = 0.26;P=0.001), previous MI (R2 = 0.17;P = 0.012), obesity (R2 = 0.22;P = 0.001), CD14+CD309+ cells (R2 = 0.058;P = 0.001), and CD14+СD309+Tie-2+ cells (R2 = 0.044;P = 0.028), NT-proBNP (R2 = 0.11;P = 0.046) were found as autonomous predictors of HFpEF. With help of multivariate Cox-regression analysis we found out, that NT-proBNP (OR 1.08; 95 % CI = 1.03–1.12; P = 0.001) and number of CD14+CD309+ cells (OR 1.07; 95 % CI = 1.02–1.11; P = 0.05) were independent predictors for HFpEF. The quantity of CD14+CD309+ cells added to NT-proBNP had more exact predictive value (OR 1.10; 95 % CI = 1.04–1.14; P = 0.001) than these biomarkers unaccompanied.

Conclusion: quantity of NT-proBNP added to CD14+CD309+ cells, cardiovascular risk influences and clinical information exhibited the best discriminate importance to differentiate HFpEF from HFrEF.

References

Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., et al. (2014) Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation, 129(3), e28–e292. doi: 10.1161/01.cir.0000441139.02102.80.

Dunlay, S. M., Manemann, S. M., Chamberlain, A. M., Cheville, A. L., Jiang, R., Weston, S. A., & Roger, V. L. (2015) Activities of daily living and outcomes in heart failure. Circ Heart Fail., 8(2), 261–7. doi: 10.1161/CIRCHEARTFAILURE.114.001542.

McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Bohm, M., Dickstein, K., et al. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail., 14(8), 803–69. doi: 10.1093/eurjhf/hfs105.

Fujisue, K., Sugiyama, S., Matsuzawa, Y., Akiyama, E., Sugamura, K., Matsubara, J., et al. (2015) Prognostic Significance of Peripheral Microvascular Endothelial Dysfunction in Heart Failure With Reduced Left Ventricular Ejection Fraction. Circ J. 79(12), 2623–31. doi: 10.1253/circj.CJ-15-0671.

Berezin, A. E. (2015) Endothelial Derived Micro Particles: Biomarkers for Heart Failure Diagnosis and Management. J Clin Trial Cardiol., 2(3), 1–3.

McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., et al., 2012. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14 (8), 803–869.

Quiñones, M. A., Douglas, P. S., Foster, E., Gorcsan, J. 3rd, Lewis, J. F., Pearlman, A. S., et al. (2003) American College of Cardiology/American Heart Association clinical competence statement on echocardiography: a report of the American College of Cardiology/American Heart Association/American College of Physicians--American Society of Internal Medicine Task Force on Clinical Competence. Circulation, 107(7), 1068–89. doi: https://doi.org/10.1161/01.CIR.0000061708.42540.47.

Tung J.W., Parks D.R., Moore W.A., et al. New approaches to fluorescence compensation and visualization of FACS data. Clin. Immunol. 2004; 110: 277-83.

Berezin A. Progenitor Cell Dysfunction: The Role of Endothelial Precursors in Heart Failure. J Biomedical Sci. 2017, 6(4): 31-33

Regueiro A, Cuadrado-Godia E, Bueno-Betí C, Diaz-Ricart M, Oliveras A, Novella S, et al. Mobilization of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: time-course after acute myocardial infarction and stroke. J Mol Cell Cardiol. 2015; 80:146-55.

Berezin A. Biomarkers in heart failure. Journal of Blood & Lymph. 2017; 7 (3): 172-179

Basile DP, Yoder MC. Circulating and tissue resident endothelial progenitor cells. J Cell Physiol. 2014; 229(1):10-6.

Downloads

How to Cite

1.
Kremzer AA. Circulating endothelial progenitor cells as a marker of left ventricular pump function in ischemic chronic heart failure. Current issues in pharmacy and medicine: science and practice [Internet]. 2017Nov.1 [cited 2024May24];(3). Available from: http://pharmed.zsmu.edu.ua/article/view/113561

Issue

Section

Experimental and clinical pharmacology